TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.

Given the company’s popularity among hedge funds and the bullish sentiment surrounding it, Tempus AI, Inc. (NASDAQ:TEM) makes ...

Key Takeaways Tempus AI stock shows 15–32% upside potential based on analyst forecasts.The company leads in using artificial ...

Tempus AI is a growth stock that is down 31% from all-time highs. Here's why TEM AI stock could be a part of your TFSA ...

The global AI infrastructure market is projected to grow at a CAGR of 29.1%, reaching $356.14 billion by 2032 from $36.59 ...

NEW ORLEANS, July 11, 2025 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 12, 2025 to file lead plaintiff applications in a ...

NEW YORK and NEW ORLEANS, July 4, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have ...

In April, Ark Research Analyst Nemo Marjanovic wrote in a weekly Ark email that Tempus AI signing a partnership with AstraZeneca and Pathos AI signaled a way to unlock new drug targets, accelerate ...

TEMPUS AI SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Tempus AI, Inc. - TEM ...

TEM INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit ...

LOS ANGELES, July 9, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Tempus AI, ...